This study is testing a drug called Surovatamig in adults aged 18 to 75 who have primary membranous nephropathy (pMN), a kidney disease where the immune system attacks the kidneys. You would be eligible if you have anti-PLA2R antibodies and have already received standard treatments like ACE inhibitors or ARBs. The main goals are to see how safe Surovatamig is, how well your body handles it, and if it helps reduce protein in your urine (a sign of kidney damage). The study plans to enroll 43 participants, but its current status is unclear.

Study design

This is a Phase II open-label study, meaning both you and your doctors will know you are receiving Surovatamig. The study plans to enroll 43 participants.

What's involved

The study involves a screening period, a treatment period where you would receive Surovatamig subcutaneously (under the skin), and a follow-up period, lasting up to 26 months in total.

Compensation

Not stated in the trial record.

Follow-up

Your health will be monitored for adverse events throughout the study, which averages 2 years. Changes in your urine protein will be measured at 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.